Please enable JavaScript to continue using this application.

Compare $IDYA vs $VKTX | Chartloom

Compare

$IDYA vs $VKTX

IDEAYA Biosciences Inc · Viking Therapeutics Inc

IDYA

IDEAYA Biosciences Inc

VKTX

Viking Therapeutics Inc

Compare $IDYA vs $VKTX

Comparing IDEAYA Biosciences Inc and Viking Therapeutics Inc

IDYAIDEAYA Biosciences Inc

VKTXViking Therapeutics Inc

IDYAIDEAYA Biosciences Inc

Market cap

$3.43B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

59.38x

Rev growth (TTM)

3244.7%

YTD performance

6.7%

52W performance

34.5%

FCF yield

-3.3%

VKTXViking Therapeutics Inc

Market cap

$3.33B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-19.5%

52W performance

-11.9%

FCF yield

-12.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

IDYA

VKTX

Detailed metrics comparison

IDYA

IDEAYA Biosciences Inc

VKTX

Viking Therapeutics Inc

Market Cap

IDYA$3.43B

VKTX$3.33B

Enterprise Value

IDYA$3.16B

VKTX$3.20B

Price

IDYA$36.11

VKTX$28.51

P/E Ratio

IDYAN/A

VKTXN/A

P/S Ratio

IDYA14.66x

VKTX0.00x

EV/Sales

IDYA13.50x

VKTX0.00x

EV/EBITDA

IDYA0.00x

VKTX0.00x

P/B Ratio

IDYA3.01x

VKTX9.38x

P/FCF Ratio

IDYAN/A

VKTXN/A

EV/FCF

IDYA-27.76x

VKTX-7.65x

PEG Ratio

IDYAN/A

VKTXN/A

Forward P/E (NTM)

IDYAN/A

VKTXN/A

Forward P/S (NTM)

IDYA59.38x

VKTXN/A

Revenue (TTM)

IDYA$234M

VKTX$0

Revenue Growth (YoY)

IDYA3244.7%

VKTXN/A

Forward Rev Growth

IDYA218.2%

VKTX236.5%

Gross Margin (TTM)

IDYA0.0%

VKTX0.0%

Operating Margin (TTM)

IDYA0.0%

VKTX0.0%

EBITDA Margin (TTM)

IDYA-91.5%

VKTX0.0%

Net Margin (TTM)

IDYA-74.8%

VKTX0.0%

FCF Margin (TTM)

IDYA-48.6%

VKTXN/A

Net Income (TTM)

IDYA$-175M

VKTX$-535M

FCF (TTM)

IDYA$-114M

VKTX$-418M

EPS (TTM)

IDYA-$1.90

VKTX-$4.60

ROE (TTM)

IDYA-1647.0%

VKTX-9456.0%

ROA (TTM)

IDYA-1511.0%

VKTX-8274.0%

ROIC (TTM)

IDYA-1647.0%

VKTX-9456.0%

Cash

IDYA$273M

VKTX$126M

Debt

IDYA$0

VKTX$0

Net Cash/Debt

IDYA$273M

VKTX$126M

Current Ratio (TTM)

IDYA10.45x

VKTX4.72x

Quick Ratio (TTM)

IDYA10.21x

VKTX4.57x

Debt/Equity (TTM)

IDYA0.00x

VKTX0.00x

Debt/Assets (TTM)

IDYA0.0%

VKTX0.0%

Interest Coverage (TTM)

IDYAN/A

VKTXN/A

Net Debt/EBITDA (TTM)

IDYA0.00x

VKTX0.00x

Beta

IDYA0.04

VKTX0.69

52W Performance

IDYA34.5%

VKTX-11.9%

YTD Performance

IDYA6.7%

VKTX-19.5%

% from 52W High

IDYA-15.4%

VKTX-33.9%

% from 52W Low

IDYA38.6%

VKTX10.6%

Asset Turnover (TTM)

IDYA0.20x

VKTX0.00x

FCF Yield (TTM)

IDYA-3.3%

VKTX-12.6%

Earnings Yield (TTM)

IDYA-5.1%

VKTX-16.1%

Dividend Yield (TTM)

IDYAN/A

VKTXN/A

Rule of 40

IDYA3,196.0

VKTX0.0

EV/GP/RG

IDYAN/A

VKTXN/A

Ticker research

View IDYA research View VKTX research

Metric	IDYA IDEAYA Biosciences Inc	VKTX Viking Therapeutics Inc
Market & Valuation
Market Cap	$3.43B	$3.33B
Enterprise Value	$3.16B	$3.20B
Price	$36.11	$28.51
P/E Ratio	N/A	N/A
P/S Ratio	14.66x	0.00x
EV/Sales	13.50x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.01x	9.38x
P/FCF Ratio	N/A	N/A
EV/FCF	-27.76x	-7.65x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	59.38x	N/A
Revenue & Growth
Revenue (TTM)	$234M	$0
Revenue Growth (YoY)	3244.7%	N/A
Forward Rev Growth	218.2%	236.5%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-91.5%	0.0%
Net Margin (TTM)	-74.8%	0.0%
FCF Margin (TTM)	-48.6%	N/A
Net Income (TTM)	$-175M	$-535M
FCF (TTM)	$-114M	$-418M
EPS (TTM)	-$1.90	-$4.60
ROE (TTM)	-1647.0%	-9456.0%
ROA (TTM)	-1511.0%	-8274.0%
ROIC (TTM)	-1647.0%	-9456.0%
Financial Health
Cash	$273M	$126M
Debt	$0	$0
Net Cash/Debt	$273M	$126M
Current Ratio (TTM)	10.45x	4.72x
Quick Ratio (TTM)	10.21x	4.57x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.04	0.69
52W Performance	34.5%	-11.9%
YTD Performance	6.7%	-19.5%
% from 52W High	-15.4%	-33.9%
% from 52W Low	38.6%	10.6%
Efficiency & Yields
Asset Turnover (TTM)	0.20x	0.00x
FCF Yield (TTM)	-3.3%	-12.6%
Earnings Yield (TTM)	-5.1%	-16.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	3,196.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View IDYA research	View VKTX research

Valuation

P/S Ratio

VKTX

0.00x

IDYA

14.66x

EV/FCF

IDYA

-27.76x

VKTX

-7.65x

Growth & revenue

Revenue Growth TTM

IDYA

3244.7%

Forward Revenue Growth

VKTX

236.5%

IDYA

218.2%

Profitability & performance

Gross Margin

IDYA

0.0%

VKTX

0.0%

ROE

IDYA

-1647.0%

VKTX

-9456.0%

FCF Yield %

IDYA

-3.3%

VKTX

-12.6%

52-Week Performance

IDYA

34.5%

VKTX

-11.9%

Detailed metrics comparison

IDYA

IDEAYA Biosciences Inc

VKTX

Viking Therapeutics Inc

Market Cap

IDYA$3.43B

VKTX$3.33B

Enterprise Value

IDYA$3.16B

VKTX$3.20B

Price

IDYA$36.11

VKTX$28.51

P/E Ratio

IDYAN/A

VKTXN/A

P/S Ratio

IDYA14.66x

VKTX0.00x

EV/Sales

IDYA13.50x

VKTX0.00x

EV/EBITDA

IDYA0.00x

VKTX0.00x

P/B Ratio

IDYA3.01x

VKTX9.38x

P/FCF Ratio

IDYAN/A

VKTXN/A

EV/FCF

IDYA-27.76x

VKTX-7.65x

PEG Ratio

IDYAN/A

VKTXN/A

Forward P/E (NTM)

IDYAN/A

VKTXN/A

Forward P/S (NTM)

IDYA59.38x

VKTXN/A

Revenue (TTM)

IDYA$234M

VKTX$0

Revenue Growth (YoY)

IDYA3244.7%

VKTXN/A

Forward Rev Growth

IDYA218.2%

VKTX236.5%

Gross Margin (TTM)

IDYA0.0%

VKTX0.0%

Operating Margin (TTM)

IDYA0.0%

VKTX0.0%

EBITDA Margin (TTM)

IDYA-91.5%

VKTX0.0%

Net Margin (TTM)

IDYA-74.8%

VKTX0.0%

FCF Margin (TTM)

IDYA-48.6%

VKTXN/A

Net Income (TTM)

IDYA$-175M

VKTX$-535M

FCF (TTM)

IDYA$-114M

VKTX$-418M

EPS (TTM)

IDYA-$1.90

VKTX-$4.60

ROE (TTM)

IDYA-1647.0%

VKTX-9456.0%

ROA (TTM)

IDYA-1511.0%

VKTX-8274.0%

ROIC (TTM)

IDYA-1647.0%

VKTX-9456.0%

Cash

IDYA$273M

VKTX$126M

Debt

IDYA$0

VKTX$0

Net Cash/Debt

IDYA$273M

VKTX$126M

Current Ratio (TTM)

IDYA10.45x

VKTX4.72x

Quick Ratio (TTM)

IDYA10.21x

VKTX4.57x

Debt/Equity (TTM)

IDYA0.00x

VKTX0.00x

Debt/Assets (TTM)

IDYA0.0%

VKTX0.0%

Interest Coverage (TTM)

IDYAN/A

VKTXN/A

Net Debt/EBITDA (TTM)

IDYA0.00x

VKTX0.00x

Beta

IDYA0.04

VKTX0.69

52W Performance

IDYA34.5%

VKTX-11.9%

YTD Performance

IDYA6.7%

VKTX-19.5%

% from 52W High

IDYA-15.4%

VKTX-33.9%

% from 52W Low

IDYA38.6%

VKTX10.6%

Asset Turnover (TTM)

IDYA0.20x

VKTX0.00x

FCF Yield (TTM)

IDYA-3.3%

VKTX-12.6%

Earnings Yield (TTM)

IDYA-5.1%

VKTX-16.1%

Dividend Yield (TTM)

IDYAN/A

VKTXN/A

Rule of 40

IDYA3,196.0

VKTX0.0

EV/GP/RG

IDYAN/A

VKTXN/A

Ticker research

View IDYA research View VKTX research

Metric	IDYA IDEAYA Biosciences Inc	VKTX Viking Therapeutics Inc
Market & Valuation
Market Cap	$3.43B	$3.33B
Enterprise Value	$3.16B	$3.20B
Price	$36.11	$28.51
P/E Ratio	N/A	N/A
P/S Ratio	14.66x	0.00x
EV/Sales	13.50x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.01x	9.38x
P/FCF Ratio	N/A	N/A
EV/FCF	-27.76x	-7.65x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	59.38x	N/A
Revenue & Growth
Revenue (TTM)	$234M	$0
Revenue Growth (YoY)	3244.7%	N/A
Forward Rev Growth	218.2%	236.5%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-91.5%	0.0%
Net Margin (TTM)	-74.8%	0.0%
FCF Margin (TTM)	-48.6%	N/A
Net Income (TTM)	$-175M	$-535M
FCF (TTM)	$-114M	$-418M
EPS (TTM)	-$1.90	-$4.60
ROE (TTM)	-1647.0%	-9456.0%
ROA (TTM)	-1511.0%	-8274.0%
ROIC (TTM)	-1647.0%	-9456.0%
Financial Health
Cash	$273M	$126M
Debt	$0	$0
Net Cash/Debt	$273M	$126M
Current Ratio (TTM)	10.45x	4.72x
Quick Ratio (TTM)	10.21x	4.57x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.04	0.69
52W Performance	34.5%	-11.9%
YTD Performance	6.7%	-19.5%
% from 52W High	-15.4%	-33.9%
% from 52W Low	38.6%	10.6%
Efficiency & Yields
Asset Turnover (TTM)	0.20x	0.00x
FCF Yield (TTM)	-3.3%	-12.6%
Earnings Yield (TTM)	-5.1%	-16.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	3,196.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View IDYA research	View VKTX research